Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DENV-1 Challenge in TDEN-PIV/TDEN-LAV Vaccinated Adults
NCT04786457Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2020
- Primary completion
- Jul 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TDENV-PIV and TDENV-LAV in dengue fever, sponsored by University of Maryland, Baltimore. Primary endpoints: Number of Participants With Solicited Injection Site Adverse Events, Number of Participants With Unsolicited Injection Site Adverse Events and 7 more. Started Nov 2020; status: completed.
02
Drugs
TDENV-PIVTDENV-LAV
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT04786457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786457.